Revenue segments as reported by the company.

Online Revenue

Wholesale Revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing

Operations and support

Technology and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Hims & Hers Health

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Hims & Hers Health achieves record revenue and profitability growth

Hims & Hers Health shows strong financial performance with revenue growth and profitability milestones.
The company's focus on customer-centric strategies, brand building, and innovation drives growth.
Challenges include competition in new categories and maintaining margins on personalized products.
Opportunities lie in expanding product offerings, improving customer experience, and leveraging efficiencies.

Hims & Hers Health excels in Q1 earnings, eyes strategic growth

Hims & Hers Health delivered robust financial performance in Q1 2023, driven by revenue growth, improved margins, and disciplined expense management.
The company's strengths lie in its focus on trusted brands, innovation in product offerings, and commitment to clinical excellence, fostering consumer trust and loyalty.
While challenges like insurance reimbursement and new category entries exist, they present opportunities for strategic growth and market differentiation in the healthcare sector.

Hims & Hers Health (HIMS) reports robust Q2 earnings, eyes personalized healthcare growth

Hims & Hers Health delivered strong financial performance in Q2, driven by revenue growth, expanded gross margins, and operational efficiency. While facing short-term challenges from pricing investments, the company remains focused on long-term growth through personalized treatments and new category launches. Opportunities lie in leveraging consumer trends towards personalized healthcare and expanding product offerings.

Hims & Hers Health reports robust Q3 performance and growth opportunities

Hims & Hers Health (HIMS) showcased strong performance, innovation, and resilience in Q3, driving revenue growth, subscriber base expansion, and improved profitability.
While challenges like achieving positive net income and balancing growth with new category launches exist, the company's strategic initiatives and focus on customer value creation position it for future success.
Opportunities in the weight management category, personalized products, and efficiency gains present avenues for HIMS to capitalize on market trends and enhance its competitive edge.
With a solid financial position, a clear marketing strategy, and a commitment to customer engagement, HIMS is poised for continued growth and value creation in the healthcare sector.

Hims & Hers Health reports stellar Q4 performance and growth outlook

Hims & Hers Health delivered a strong performance in Q4 2023, with robust revenue growth, positive net income, and expanded gross margins.
The company's focus on personalized solutions, subscriber growth, and financial strength positions it well for future growth and market expansion.
While facing challenges in managing costs and margin expansion, HIMS has opportunities to drive revenue growth, enhance user experience, and offer a diverse product range.
By balancing its strengths, addressing challenges, and seizing opportunities, Hims & Hers Health is poised for continued success in the healthcare market.

Hims & Hers Health reports stellar Q1 results and eyes expansion

Hims & Hers Health's Q1 2024 performance reflects strong financial growth, driven by record subscriber numbers and revenue increase, underpinned by a strategic focus on personalized care and enhancing customer experience.
The company's strengths lie in their ability to drive consumer adoption through user-friendly solutions, capitalize on the rapid growth of the Hers segment, and maintain consumer confidence through strategic pricing initiatives.
While facing challenges in scaling operations and managing increased capital expenditures, HIMS has ample opportunities to expand their offerings, invest in new product categories, and drive further revenue growth through strategic pricing adjustments.

Hims & Hers Health posts stellar Q2 results, eyes revenue diversification

Hims & Hers Health (HIMS) reported impressive Q2 performance, with strong revenue growth and subscriber additions.
The company's strategic initiatives in weight management and sterile compounded medications position it for future success.
While facing challenges in data availability and market dynamics, Hims & Hers has opportunities for revenue diversification and enhanced customer engagement.

Hims & Hers Health (HIMS) reports stellar Q3 results and eyes growth through personalized healthcare

Hims & Hers Health's Q3 performance reflects strong revenue growth, subscriber expansion, and improved profitability, positioning the company for continued success.
While facing challenges in retention and operational efficiency, the company's strategic initiatives and market positioning offer opportunities for sustained growth and innovation.
With a focus on personalized healthcare solutions and social responsibility, Hims & Hers Health is well-positioned to capitalize on market opportunities and drive long-term value for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hims was founded in November 2017 after Andrew Dudum was called out by his sister for having dry skin and breakouts. After she ordered him expensive products to address his issues, Dudum realized that men don't have the same options as women when it comes to purchasing wellness products. 

Now with radiant skin, Andrew Dudum and Jack Abraham co-found HIMS as an Atomic (VC fund) portfolio company. The company initially sells hair loss treatments, biotin vitamins, shampoo, and erectile dysfunction treatments. 

The company raises $7 million in Series A from M/C Partners, SV Angel and Thrive Captial, putting its pre-money valuation at $13 million.

Hims raises $40 million in Series B led by IVP and Redpoint Ventures, putting its pre-money valuation at $160 million. 

Hims launches a women's brand, Hers. 

Hers offers telemedicine services, birth control, and non-prescription hair and skin-care products. 

The company partners with A-list couple Jennifer Lopez and Alex Rodriguez, who work with the company on the launch of new products. 

Hims raises $297 million in Series C funding led by DCM Ventures, NewView Capital, McKesson Ventures, putting its valuation at $1 billion.

Hims and Hers expands into virtual mental health services led by licensed professionals, with support groups available free of charge during the COVID-19 pandemic. 

The company now provides access to medical care and treatment for more than a dozen conditions with more than 50 products, and has facilitated 1 million medical visits through its telehealth platforms in 2019. 

Hims goes public through a merger with a blank-check company Oaktree Acquisition Corp at $1.6 billion valuation.

forhims.com/aboutus
forhims.com/investors
SEC
CNBC
Business Insider
Bloomberg
Crunchbase
Axios

Hims & Hers Health is a high growth, healthcare startup stepping into the GLP-1 space.

HIMS Stock Tumbles: Here's Why It's a Buy Right Now

A short report was published that makes a case against Hims & Hers' new GLP-1 product. The report was put out by a media organization with ties to a fund that is also a short-seller of the stock.

Hims & Hers Stock Drops 12.8% After Short Report

Hims & Hers Health (NYSE: HIMS ) stock is taking a tumble after Hunterbrook Media released a short report on the telehealth company. Hunterbrook operates an interesting business model, as it publishes research on stocks through Hunterbrook Media while sometimes taking a position in the same stock through its hedge fund affiliate, Hunterbrook Capital.

Short Seller Hunterbrook Slams Hims & Hers (HIMS) Stock in New Report

Cava Group, Inc.

Consumer spending on healthcare and restaurants is resilient in a range of economic environments. Hims & Hers is tapping into the potential of the lucrative telehealth market.

2 Top Growth Stocks to Buy With $500 Right Now

In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $22.15, marking no change from the previous day.

Hims & Hers Health, Inc. (HIMS) Flat As Market Sinks: What You Should Know

The telehealth company is offering innovative products at lower prices.

Should You Buy Hims & Hers Health Stock Right Now?

Enovis Corp

Standard BioTools Inc

Pulmonx

Phreesia Inc

We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.

5 Medical Info Systems Stock to Buy for a Stable Portfolio

After a parabolic run in recent months, HIMS stock took a double-digit plunge last week in an apparent loss of technical momentum. While its technical correction may lead to a deeper pullback in the near term, Hims & Hers' robust business momentum is likely to persist for years to come. Considering HIMS' depressed valuation and lucrative long-term risk/reward, I remain bullish on Hims & Hers' stock.

Hims & Hers: Buy The Dip To Catch The Next Rip

Summer has officially begun, but some stocks are receiving a chilly reception today.

3 Reasons to Buy Hims & Hers Health Stock Now

As of this article being written, Hims & Hers Health is up around 33% since the announcement that they will offer GLP-1 Injections for as low as $199 a month. Reports that the company has already started shipping out injections to subscribers. HIMS stock is still undervalued despite the recent run-up in price, initiating a Buy rating based on subscriber growth, GLP-1 sales estimates, and increased revenues.

Hims & Hers: The Undervalued Gem Poised For Growth

Hims & Hers has rallied substantially this year as it started to show its profitability chops. Despite guiding for a >$1 billion annualized revenue scale in 2024, the company is still expected to grow revenue north of 40%+ and have 80%+ pro forma gross margins. The company believes it can expand its adjusted EBITDA margins to a steady rate of 20-30% (versus low teens today).

Hims & Hers: Ready For Takeoff

Foot Locker

Shake Shack

One of the market's most closely watched economic reports made a sudden turn last week. The employment situation report (NFP) showed that the U.S. economy is still resiliently adding jobs despite seeing some contradicting indicators placing a ceiling on its growth.

3 Sector Stars Lead Growth: Foot Locker, Shake Shack, Hims & Hers

Abercrombie & Fitch

Chewy

Gap Inc

Vital Farms, Inc.

VITL, HIMS, ANF, CHWY and GPS are five stocks with explosive relative price strength.

5 Phenomenal Relative Price Strength Stocks to Snap Up Now

Him & Hers Health Inc. NYSE: HIMS provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments for erectile dysfunction (ED) through brand and generic versions of Pfizer Inc. NYSE: PFE Viagra (Sildenafil) and Eli Lilly & Co. NYSE: LLY Cialis (Tadalafil).

Hims & Hers Health Soars on Generic GLP-1 Rollout Plans

Hims & Hers recently launched weight loss drugs at a disruptive price point. The company is growing revenue quickly.

Hims & Hers Health Stock Soared This Week: Here's Why

Bloom Energy

As the saying goes, always follow the money. This time, investors can follow the proverbial big players through an options activity screener, spotting unusual trends in how markets are betting.

Call Option Volumes Spiked For These 3 Stocks

Health Catalyst Inc

Zacks Medical Info Systems industry stocks like Hims & Hers Health (HIMS), Enovis Corporation (ENOV) and Health Catalyst (HCAT) are expected to gain from the GenAI wave.

3 Medical Info Systems Stocks to Buy as GenAI Transforms Healthcare

Hims & Hers has entered the popular GLP-1 agonist category. Weight loss has quickly become a significant, potentially unexpected catalyst.

The Ultimate Growth Stock to Buy With $20 Right Now

ACM Research

Advanced Micro Devices

Intel

NVIDIA

SoFi Technologies

Block

If you're wondering which stocks to buy for the next economic upturn, you're in the right place. Finding profitable investment opportunities in the constantly changing global economy is crucial to profiting from the next economic boom.

7 Stocks to Dominate in the Next Economic Upturn

Mangoceuticals Inc

Nestle SA

For investors looking at companies providing GLP-1 drugs, there are certainly plenty of factors to consider. This is a fast-growing market, but one also becoming increasingly competitive.

Move Over Ozempic! 3 New GLP-1 Drugs and Products Coming Soon.

ChargePoint Holdings

Virgin Galactic

Judging which growth stocks are good long-term bets is trickier than you might expect. These fast-moving businesses can be hard to forecast, and changes in their broader industries could quickly lift up (or sink) these growth names in short order.

The Growth Stock Shuffle: 2 to Ditch and 1 to Own

GLP-1s could be the product that pushes Hims & Hers over the edge to mainstream adoption.

Hims & Hers Is Changing the Game

Health and wellness company Hims & Hers announced Monday that it is introducing injectable weight-loss drugs at a fraction of the cost of Ozempic and Wegovy.

Hims & Hers rolls out weight-loss shots much cheaper than Ozempic, Wegovy

Hims & Hers Health got a shot in the arm this week that sent its share prices to near all-time highs.

Hims & Hers Health stock price nears record high on news that it will offer GLP-1 weight-loss drugs amid shortages

Hims & Hers Health's share price increased by over 25% after announcing the availability of compounded GLP-1 agonist weight loss drugs at a fraction of the price of branded drugs. The company aims to capitalize on the shortages of the branded drugs Wegovy and Zepbound, which are expected to dominate a potential $100 billion industry. Hims & Hers' partnership with a manufacturer of generic and compounded medications allows it to offer these drugs without supply shortages, potentially generating significant revenue.

News for Hims & Hers Health Stock (HIMS)